Literature DB >> 6214666

Progressive passive Heymann nephritis in the rat.

A Z Barabas, N Boyd, J Cornish, R Lannigan.   

Abstract

Progressive passive Heymann nephritis was produced in rats by simultaneous intravenous injections of heterologous antirat glomerular basement membrane antiserum and heterologous antirat kidney tubular fraction 3 antibody. The animals were killed at 16 weeks by which time approximately one-half of them were severely proteinuric. The glomeruli showed beaded immune deposits around the capillaries by immunofluorescence, and on electron microscopy osmiophilic deposits were noted in the subepithelial zones and within the glomerular basement membrane. The lesion resembled that of severe Heymann nephritis. gamma-Globulin eluted from the kidneys contained an autologous IgG that reacted with the brush border region of the renal proximal tubules of normal rats. This component was present in proteinuric and nonproteinuric animals. It is concluded that the progression results from the development of autoantibodies to the tubular nephritogenic antigen and the proteinuria is related to increasing deposition of immune complexes in the glomeruli.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214666

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  3 in total

1.  Epitope specificity of anti-gp330 autoantibodies determines the development of proteinuria in active Heymann nephritis.

Authors:  E H Van Leer; P Ronco; P Verroust; A M van der Wal; P J Hoedemaeker; E De Heer
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

2.  Stimulation of circulating autoantibody levels in the rat with established progressive passive Heymann nephritis.

Authors:  A Z Barabas; J Cornish; R Lannigan
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

3.  Progressive passive Heymann nephritis: induction of autologous antibodies to rat brush border by multiple injections of heterologous antiserum.

Authors:  A Z Barabas; J Cornish; R Lannigan
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.